ADAM-23 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAM-23 (UniProt O75077), HEK293-expressed. A non-catalytic ADAM family member studied in synaptic organisation, epilepsy genetics, and cancer biology research.
Expression system
HEK293
Cat. #
REC-ADAM23

In stock

SKU
REC-ADAM23
$498.00

Target Overview

ADAM-23 (UniProt O75077; gene: ADAM23) is an 832-amino-acid, non-catalytic member of the ADAM (a disintegrin and metalloproteinase) family, also catalogued under the historical designation MDC-3 (metalloproteinase-like, disintegrin-like, and cysteine-rich protein 3). Unlike proteolytically active ADAMs, ADAM-23 lacks a functional metalloprotease active site, classifying it as a catalytically inactive scaffold or adhesion protein. It is anchored at the cell membrane, where published data support roles in cell–cell and cell–matrix interactions, with particular relevance to synaptic organisation through its physical association with LGI1 and ADAM22 within a trans-synaptic protein complex. This recombinant is expressed in HEK293 cells, a mammalian system that preserves the glycosylation and disulfide-bonding patterns characteristic of the native extracellular domains — features that are important when studying protein–protein interactions involving the disintegrin-like and cysteine-rich regions. The full-length human sequence (832 residues) is encoded by a construct validated for human reactivity; mouse, non-human primate, dog, and pan cross-reactivity are additionally predicted based on sequence homology. Researchers use this recombinant in several experimental contexts: as a binding partner in pull-down and co-immunoprecipitation assays interrogating the LGI1–ADAM22–ADAM23–DLG4 complex; as a positive-control antigen in antibody validation workflows (Western blot and IHC); and as a defined antigen in ELISA-based detection of anti-ADAM23 autoantibodies. Investigators working on epitranscriptomic regulation of ADAM23 expression in oncology models have also applied recombinant ADAM23 as a reference standard for quantitative proteomics normalisation. Researchers requiring an antibody reagent matched to this recombinant can pair it with the Triple Point Biologics anti-ADAM23 antibody (SKU: RP-ADAM23).

Background

ADAM-23 is a membrane-anchored, catalytically inactive member of the ADAM superfamily, encoded by the ADAM23 gene. Its domain architecture — retaining disintegrin-like, cysteine-rich, and EGF-like regions despite an inactivated metalloprotease domain — positions it as a structural and adhesive component rather than a sheddase or proteinase. Research over the past two decades has established ADAM-23 as a constituent of a trans-synaptic protein complex centred on leucine-rich glioma-inactivated protein 1 (LGI1), together with ADAM22 and the postsynaptic scaffolding protein DLG4 (PSD-95). The functional importance of this complex in the central nervous system has been explored through multiple research angles. A 2026 gene burden meta-analysis across 748,879 individuals identified association of rare, damaging variants in ADAM23 and other LGI1-complex genes with epilepsy, framing ADAM23 as a research target for understanding synaptic excitability (Lal JC et al., Epilepsia, 2026; PMID 42216960). Separately, mass-spectrometry-based immunoprecipitation studies of autoimmune encephalitis cases carrying LGI1 antibodies detected co-precipitation of ADAM23 alongside ADAM22 and DLG4, demonstrating that recombinant and native ADAM23 share epitopes relevant to autoantibody research (Kudo A et al., Intern Med, 2026; PMID 42309678). These findings have driven interest in recombinant ADAM23 as an antigen standard for autoantibody detection assays. Beyond neuroscience, ADAM23 has been characterised as an m6A-methylation-regulated gene in the context of platinum resistance in ovarian cancer cell models, with METTL3-dependent epitranscriptomic control modulating ADAM23 transcript stability and protein output (Kim U et al., Cells, 2026; PMID 41677656). This line of research uses recombinant ADAM23 as a reference for quantitative protein-level comparisons across treatment conditions. Neuroanatomical studies examining dentate gyrus remodelling after entorhinal denervation in mice have documented spatiotemporally regulated changes in Adam23 gene expression, supporting its use in rodent circuit-remodelling research (Schlaudraff J et al., Front Mol Neurosci, 2026; PMID 42239799). Additionally, imprinting analyses across mammalian species have identified species-specific parent-of-origin expression patterns of Adam23 in brain tissue, with implications for studying monoallelic expression mechanisms (Meguro-Horike M et al., Genes Cells, 2026; PMID 41568889). Taken together, the published literature positions recombinant ADAM-23 as a versatile reagent for pull-down and co-IP assays, autoantibody detection, antibody validation, and quantitative expression studies across neuroscience and oncology research programmes.

Applications

  • LGI1–ADAM22–ADAM23–DLG4 complex pull-down and co-immunoprecipitation assays
  • Antibody validation positive control for Western blot using matched anti-ADAM23 antibody (RP-ADAM23)
  • ELISA-based detection and titration of anti-ADAM23 autoantibodies in patient-derived serum samples
  • Protein–protein interaction binding assays (e.g., surface plasmon resonance or bio-layer interferometry) with LGI1 or ADAM22 as binding partners
  • Recombinant antigen standard for quantitative proteomics normalisation in ADAM23 expression studies
  • Competitive immunoprecipitation and epitope-mapping experiments for anti-LGI1-complex autoantibody research
  • Reference antigen in m6A-epitranscriptomic regulation studies examining METTL3-dependent ADAM23 protein output

References

  1. Kudo A et al. Association between the peptide spectrum match values of LGI1, ADAM22, ADAM23 and DLG4 in the immunoprecipitation products of five autoimmune encephalitis cases with LGI1 antibody: A case series. Intern Med. 2026. doi:10.2169/internalmedicine.6503-25. PMID: 42309678.
  2. Schlaudraff J et al. Spatiotemporal patterns of gene expression changes in the mouse dentate gyrus following entorhinal denervation. Front Mol Neurosci. 2026. doi:10.3389/fnmol.2026.1758390. PMID: 42239799.
  3. Lal JC et al. Gene burden meta-analysis of 748,879 individuals identifies LGI1-ADAM23 protein complex association with epilepsy. Epilepsia. 2026. doi:10.1002/epi.70299. PMID: 42216960.
  4. Kim U et al. Epitranscriptomic Regulation of Platinum Resistance via the METTL3-ADAM23 Axis in Ovarian Cancer. Cells. 2026. doi:10.3390/cells15030294. PMID: 41677656.
  5. Meguro-Horike M et al. Species-Specific Parent-Of-Origin Expression of Adam23 in the Mammalian Brain. Genes Cells. 2026. doi:10.1111/gtc.70086. PMID: 41568889.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type I transmembrane; cell surface; Golgi → endosomes

Frequently Asked Questions

What molecular weight does recombinant ADAM-23 run at on SDS-PAGE or Western blot?

The ADAM-23 coding sequence predicts a theoretical molecular weight of approximately 93 kDa from its 832 amino acids, but the HEK293-expressed recombinant typically migrates at 100–115 kDa under reducing SDS-PAGE conditions due to N-linked glycosylation across multiple extracellular domain sites. Under non-reducing conditions, intramolecular disulfide bonds in the cysteine-rich domain can compress apparent mobility slightly. When running this protein as a positive control alongside RP-ADAM23 on Western blot, expect the primary band in the 100–115 kDa window; faint lower bands may reflect partial deglycosylation during sample prep.

Is recombinant ADAM-23 a full-length protein or a processed extracellular domain fragment?

The REC-ADAM23 construct covers the mature ectodomain — prodomain through cysteine-rich region — and excludes the transmembrane anchor and cytoplasmic tail. This design reflects the fact that ADAM-23's functionally characterised interactions (with LGI1 and ADAM22 in the trans-synaptic complex) are mediated entirely by extracellular domains. Full-length ADAM-23 undergoes prodomain removal during biosynthetic trafficking; the recombinant is supplied post-prodomain cleavage, representing the processed, membrane-competent form relevant to binding and scaffolding experiments.

Does ADAM-23 have metalloprotease activity, and what substrates should I use to test it?

ADAM-23 is a catalytically inactive ADAM family member. Its metalloprotease domain lacks the consensus HExxHxxGxxH zinc-binding motif required for catalysis, so it will not cleave generic ADAM substrates such as Mca-PLAQAV-Dpa-RSSSR-NH2 or quenched fluorescent peptides based on TNF-α or EGF-R sequences. Do not use standard ADAM activity assays to evaluate this protein — they will return a flat signal, which is the expected result. ADAM-23 is best characterised in binding assays (SPR, co-IP, pull-down) probing its disintegrin-like or cysteine-rich domain interactions with LGI1 or ADAM22.

What buffer conditions are recommended for ADAM-23 binding assays or pull-down experiments?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. For pull-down or co-immunoprecipitation experiments probing LGI1 or ADAM22 binding, this buffer is compatible as-is; glycerol stabilises the cysteine-rich domain during incubation. If you are diluting into a cell lysate binding buffer (e.g., 25 mM HEPES pH 7.4, 150 mM NaCl, 0.5% NP-40), keep final glycerol below 2% to avoid viscosity artefacts. Because ADAM-23 is not a metalloproteinase, CaCl2 supplementation is not required but is not harmful at 1–2 mM.

What starting concentration of recombinant ADAM-23 should I use for a protein–protein interaction binding assay?

For surface plasmon resonance or bio-layer interferometry with LGI1 or ADAM22 as the analyte, a concentration series of 5–500 nM ADAM-23 in running buffer (PBS pH 7.4, 0.05% Tween-20) gives a workable signal window based on published KD values in the low-nanomolar range. For pull-down experiments from HEK293 or neuronal lysates, 0.5–2 µg of recombinant protein per 500 µg total lysate is a reasonable starting point. Titrate downward if non-specific binding to beads is observed; the >95% purity specification minimises but does not eliminate background.

Can I use REC-ADAM23 as a positive control for Western blot when validating the RP-ADAM23 rabbit polyclonal antibody?

Yes — this is one of the primary intended uses. Load 20–50 ng of REC-ADAM23 per lane alongside your cell lysate samples. The matched antibody RP-ADAM23 (see /anti-adam-23-rabbit-polyclonal-antibody) is raised against the same ectodomain region present in this recombinant, so epitope accessibility is guaranteed. Run under reducing conditions; expect a clean band at 100–115 kDa. This pairing is also useful for antibody titration: a dilution series of RP-ADAM23 (typically 1:500–1:5000) against 30–50 ng recombinant defines the linear detection range before applying the antibody to tissue lysates.

How much REC-ADAM23 should I load for a Western blot positive control lane?

20–50 ng per lane is sufficient for a strong, clean signal with RP-ADAM23 at 1:1000–1:2000 dilution on a standard PVDF membrane. At 50 ng you will see a robust band at approximately 100–115 kDa with minimal background. Avoid loading above 100 ng unless you are specifically characterising antibody saturation — overloading a glycosylated recombinant can produce a smeared upper band that may be mistaken for a doublet. Denature samples at 95°C for 5 minutes in reducing Laemmli buffer; the disulfide-rich cysteine domain requires complete reduction for sharp migration.

How should I store and handle REC-ADAM23 to maintain activity across multiple experiments?

REC-ADAM23 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and shipped on dry ice. Upon receipt, aliquot immediately into single-use volumes (typically 5–10 µg per tube) and store at −20°C. Avoid repeated freeze-thaw cycles; each cycle can promote aggregation of the cysteine-rich domain and reduce binding competence measurable in pull-down assays. For short-term use (up to 48 hours), the protein is stable at 4°C. Do not dilute working aliquots more than 1:10 below the supplied concentration without adding 0.1% BSA as a carrier to prevent adsorptive loss to tube surfaces.

Validation imagery coming soon

Western blot validation figures for REC-ADAM23 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →